Atopic dermatitis sufferers may benefit from a new therapy on the horizon. Only two years after researchers behind one novel atopic dermatitis drug asserted that atopic dermatitis is an autoimmune disease, a totally different therapeutic approach may be on its way. Between 1 and 3 percent of adults suffer from eczema, but 10 to 20 percent of children have this autoimmune condition, according to a paper in the Annals of Nutrition and Metabolism. What’s more, six out of every 10 infants who have eczema will continue to have one or more symptoms of it into adulthood. Products to treat atopic dermatitis are in high demand. Among the most interesting of the novel atopic dermatitis treatments that may be available is a therapy that will involve bacterial transplants.
People with atopic dermatitis may soon have the option of applying a cream made from bacteria that secrete antimicrobial peptides to treat their eczema. While it may seem unusual to apply bacteria to broken, irritated skin, researchers say that this might be exactly what is needed to combat Staphylococcus aureus infections or colonization among eczema sufferers. It is now common for this type of bacteria to be resistant to antibiotics once used to fight it. Often presenting as boils, severe rashes, or abscesses, MRSA infections are a major worry for parents of children with atopic dermatitis.